One might cite Bausch Health acquiring Dendreon, an OTC-traded company, for $400 million, or AbbVie acquiring Allergan for something like $63 billion in 2019.

The main point to make is that Leron is a unicorn, and you like the rest of it know it. No OTC has ever owned a platform drug that might very well be of use in 90+ indications.

So no comparison can be made, which makes your point moot.